High Dose Interleukin-2 Therapy

Petrulio, Christian; DeRaffele, Gail; Kaufman, Howard L.

doi:10.1007/978-1-4020-6087-8_19

Cited by 1 publication

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 IL-2 is a therapy shown to be beneficial specifically for clear cell RCC patients with metastatic disease, where 94% of clear cell RCC patients have carbonic anhydrase IX, a RCC marker associated with better IL-2 outcomes. 14 When IL-2 is administered in high-dose, intravenous form, patients experience severe side effects. 1, 13, 15–22 Thus far, the long-term impact of IL-2 treatments on cognition and affect has not been thoroughly described.…”

Section: Introductionmentioning

confidence: 99%

Cognitive and Affective Symptoms Experienced by Cancer Patients Receiving High-Dose Intravenous Interleukin 2 Therapy

2016

View full text Add to dashboard Cite

Background Alterations in cognitive/affective functioning are among the most challenging side effects experienced by 80% of patients with metastatic melanoma and metastatic renal cell carcinoma undergoing high-dose Interleukin-2 (IL-2) therapy. Objective The purpose of this literature review is to describe what is known about IL-2—induced cognitive/affective symptoms, their prevalence and level of severity, and synthesize findings to determine areas for future research to address symptom management challenges. This review describes the IL-2 patient experience, and the pathophysiology leading to these changes. Methods An online electronic search using PubMed was performed to identify relevant literature published between 1992 and 2015. Of the original 113 manuscripts, information was extracted from nine articles regarding cognitive symptoms, affective symptoms, sample size, research design, reliability and validity. Results Our review suggests that the trajectories, breadth and depth of cognitive/affective symptoms have yet to be described. Despite intervention studies designed to address the psychosocial complications of IL-2, an understanding of the level of altered cognitive/affective symptoms experienced by IL-2 patients remains unclear. Conclusion Our literature review reveals a lack of standardization when assessing, reporting and managing cognitive/affective symptoms. Patients/family members have reported cognitive/affective symptoms to be the most alarming and difficult symptoms, yet these symptoms are not adequately screened for and patients were not informed about potential changes. Implications for Practice Assessing patients for cognitive/affective alterations is important to reduce anxiety while improving outcomes. Education about the illness trajectory (what to expect during/after treatment) can help care partners/patients set realistic shared expectations, and increase coping.

show abstract

Section: Introductionmentioning

confidence: 99%